BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 24992469)

  • 1. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry.
    Chung L; Farber HW; Benza R; Miller DP; Parsons L; Hassoun PM; McGoon M; Nicolls MR; Zamanian RT
    Chest; 2014 Dec; 146(6):1494-1504. PubMed ID: 24992469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.
    Chung L; Liu J; Parsons L; Hassoun PM; McGoon M; Badesch DB; Miller DP; Nicolls MR; Zamanian RT
    Chest; 2010 Dec; 138(6):1383-94. PubMed ID: 20507945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension.
    Xanthouli P; Jordan S; Milde N; Marra A; Blank N; Egenlauf B; Gorenflo M; Harutyunova S; Lorenz HM; Nagel C; Theobald V; Lichtblau M; Berlier C; Ulrich S; Grünig E; Benjamin N; Distler O
    Ann Rheum Dis; 2020 Mar; 79(3):370-378. PubMed ID: 31818805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry.
    Barst RJ; Chung L; Zamanian RT; Turner M; McGoon MD
    Chest; 2013 Jul; 144(1):160-168. PubMed ID: 23429998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China.
    Zhao J; Wang Q; Liu Y; Tian Z; Guo X; Wang H; Lai J; Huang C; Yang X; Li M; Zeng X
    Int J Cardiol; 2017 Jun; 236():432-437. PubMed ID: 28159359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors of mortality and 2-year survival analysis of systemic sclerosis with pulmonary arterial hypertension in Thailand.
    Foocharoen C; Nanagara R; Kiatchoosakun S; Suwannaroj S; Mahakkanukrauh A
    Int J Rheum Dis; 2011 Aug; 14(3):282-9. PubMed ID: 21816025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension.
    Campo A; Mathai SC; Le Pavec J; Zaiman AL; Hummers LK; Boyce D; Housten T; Champion HC; Lechtzin N; Wigley FM; Girgis RE; Hassoun PM
    Am J Respir Crit Care Med; 2010 Jul; 182(2):252-60. PubMed ID: 20339143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry.
    Chung L; Domsic RT; Lingala B; Alkassab F; Bolster M; Csuka ME; Derk C; Fischer A; Frech T; Furst DE; Gomberg-Maitland M; Hinchcliff M; Hsu V; Hummers LK; Khanna D; Medsger TA; Molitor JA; Preston IR; Schiopu E; Shapiro L; Silver R; Simms R; Varga J; Gordon JK; Steen VD
    Arthritis Care Res (Hoboken); 2014 Mar; 66(3):489-95. PubMed ID: 23983198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and Survival of Anti-U1 RNP Antibody-Positive Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.
    Sobanski V; Giovannelli J; Lynch BM; Schreiber BE; Nihtyanova SI; Harvey J; Handler CE; Denton CP; Coghlan JG
    Arthritis Rheumatol; 2016 Feb; 68(2):484-93. PubMed ID: 26415038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS).
    Kolstad KD; Li S; Steen V; Chung L;
    Chest; 2018 Oct; 154(4):862-871. PubMed ID: 29777655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
    Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE
    Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease.
    Volkmann ER; Saggar R; Khanna D; Torres B; Flora A; Yoder L; Clements PJ; Elashoff RM; Ross DJ; Agrawal H; Borazan N; Furst DE; Saggar R
    Arthritis Rheumatol; 2014 Jul; 66(7):1900-8. PubMed ID: 24729406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort.
    Noviani M; Saffari SE; Tan JL; Yip JWL; Teng GG; Law WG; Chan GYL; Santosa A; Lim AYN; Hong C; Ng SA; Tay ELW; Ruan W; Yap J; Low AHL
    Semin Arthritis Rheum; 2020 Jun; 50(3):473-479. PubMed ID: 31810742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH.
    Clements PJ; Tan M; McLaughlin VV; Oudiz RJ; Tapson VF; Channick RN; Rubin LJ; Langer A;
    Ann Rheum Dis; 2012 Feb; 71(2):249-52. PubMed ID: 21998119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining the necessity for right heart catheterization in pulmonary hypertension associated with connective tissue diseases assessed by echocardiography.
    Choi JH; Joo SJ; Kim J
    Int J Rheum Dis; 2016 Jan; 19(1):65-73. PubMed ID: 26820839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.
    Allanore Y; Borderie D; Avouac J; Zerkak D; Meune C; Hachulla E; Mouthon L; Guillevin L; Meyer O; Ekindjian OG; Weber S; Kahan A
    Arthritis Rheum; 2008 Jan; 58(1):284-91. PubMed ID: 18163505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension.
    Weatherald J; Boucly A; Launay D; Cottin V; Prévot G; Bourlier D; Dauphin C; Chaouat A; Savale L; Jaïs X; Jevnikar M; Traclet J; De Groote P; Simonneau G; Hachulla E; Mouthon L; Montani D; Humbert M; Sitbon O
    Eur Respir J; 2018 Oct; 52(4):. PubMed ID: 30209196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the REVEAL Prognostic Equation and Risk Score Calculator in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.
    Mullin CJ; Khair RM; Damico RL; Kolb TM; Hummers LK; Hassoun PM; Steen VD; Mathai SC;
    Arthritis Rheumatol; 2019 Oct; 71(10):1691-1700. PubMed ID: 31066998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival.
    Humbert M; Yaici A; de Groote P; Montani D; Sitbon O; Launay D; Gressin V; Guillevin L; Clerson P; Simonneau G; Hachulla E
    Arthritis Rheum; 2011 Nov; 63(11):3522-30. PubMed ID: 21769843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry.
    Hinchcliff M; Khanna S; Hsu VM; Lee J; Almagor O; Chang RW; Steen V; Chung L;
    Semin Arthritis Rheum; 2015 Dec; 45(3):309-14. PubMed ID: 26210782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.